| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 02/06/2002 | EP1178115A2 Phosphodiesterase |
| 02/06/2002 | EP1177312A2 Human gil-19/ae289 proteins and polynucleotides encoding same |
| 02/06/2002 | EP1177297A2 Novel nucleic acids and proteins with growth hormone activity |
| 02/06/2002 | EP1177296A2 Extracellular matrix and adhesion-associated proteins |
| 02/06/2002 | EP1177195A1 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV |
| 02/06/2002 | EP1177181A1 Substituted bicyclic compounds |
| 02/06/2002 | EP1177178A1 Heterocyclically substituted benzimidazoles, the production and application thereof |
| 02/06/2002 | EP1177175A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 02/06/2002 | EP1177168A1 Caspase inhibitors and the use thereof |
| 02/06/2002 | EP1176985A2 Enzymatically activated polymeric drug conjugates |
| 02/06/2002 | EP1176982A1 Prucalopride oral solution |
| 02/06/2002 | EP1176981A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| 02/06/2002 | EP1176980A1 Ccr4 antagonists in sepsis |
| 02/06/2002 | EP1176975A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| 02/06/2002 | EP1176972A1 Use of phyllanthus for targeted stimulation of the immune system |
| 02/06/2002 | EP1176971A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes |
| 02/06/2002 | EP1176963A2 Use of dopamine d 3? receptor ligands for producing medicaments for treating kidney disorders |
| 02/06/2002 | EP1162990A4 Treatment with small peptides to effect antifibrotic activity |
| 02/06/2002 | EP0971917B1 Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties |
| 02/06/2002 | EP0843551B1 Endothelin receptor antagonists |
| 02/06/2002 | EP0771198B1 Dihydro-2,3-benzodiazepine derivatives |
| 02/06/2002 | CN1334820A Connective tissue growth factor fragments and methods and uses thereof |
| 02/06/2002 | CN1334819A Connective tissue growth factor fragments and methods and uses thereof |
| 02/06/2002 | CN1334813A Method for preparing (R)-(+)-3-{1-[2-(4-benzoyl-2-(3,4-difluorophenyl) morpholin-2-yl)ethyl]-4-phenylpiperdin-4-yl}-1,1-dimethylurea, its salts solvates and/or hydrates |
| 02/06/2002 | CN1334806A Beta-amide and beta-sulfonamide carboxylic acid derivs., their preparation and their use as endothelin receptor antagonists |
| 02/06/2002 | CN1334726A Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists |
| 02/06/2002 | CN1334118A Chinese medicine for treating uremia |
| 02/06/2002 | CN1334100A Medicine composition for treating nephrosis and its preparing process |
| 02/06/2002 | CN1334092A Anorectal medicine for treating prostatitis |
| 02/06/2002 | CN1334015A Bagged kidney tea |
| 02/06/2002 | CN1078889C Non-pepitde tachykinin receptor antagonists |
| 02/05/2002 | WO2002034268A1 Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2-[2-[4-(2-methoxyphenyl)piperazinyl]ethylamino]pyrimidine trihydrochloride as active ingredient |
| 02/05/2002 | US6344562 Thiazole derivatives |
| 02/05/2002 | US6344475 Cystic fibrosis |
| 02/05/2002 | US6344468 Substituted isoindolones and their use as cyclic GMP modulators in medicaments |
| 02/05/2002 | US6344463 Skin disorders, acne |
| 02/05/2002 | US6344441 Lipoprotein-regulating medicaments |
| 01/31/2002 | WO2002008396A2 Human proteases |
| 01/31/2002 | WO2002008285A2 Il-17 molecules and uses thereof |
| 01/31/2002 | WO2002008271A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | WO2002008255A2 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | WO2002008232A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 01/31/2002 | WO2002008231A2 Biologically active macrolides, compositions, and uses thereof |
| 01/31/2002 | WO2002008221A2 Capsaicin receptor ligands |
| 01/31/2002 | WO2002008218A1 Cyclic substituted aminomethyl compounds and medicaments containing said compounds |
| 01/31/2002 | WO2002008212A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | WO2002008210A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | WO2002008185A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | WO2002008178A1 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
| 01/31/2002 | WO2002007727A1 Use of pyridazino(4,5-)indole-1-acetamide derivatives for preparing medicines for treating pathologies related to the dysfunction of peripheral benzodiazepin receptors |
| 01/31/2002 | WO2002007725A1 Method for treating fibrotic diseases or other indications ic |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | US20020013484 Water solubility; prodrug containing polyether oligomer |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013321 Used as ligands for opioid receptors, for therapy of neurological and gastrointestinal disorders |
| 01/31/2002 | US20020013297 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013256 Novel inhibitors of formation of advanced glycation endproducts (AGES) |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | US20020012708 For preparation of medicaments for treatment of organ and tissue damages caused by radiation, infections, and chemically, especially of O-MALT system of small intestine, bone marrow, spleen, lymph nodes, liver |
| 01/31/2002 | DE19881732C1 New phosphodiesterase inhibiting 2-phenyl-imidazotriazinone derivatives useful for treating e.g. cardiovascular, cerebrovascular and/or urogenital diseases |
| 01/31/2002 | CA2418215A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2415740A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | CA2415606A1 Capsaicin receptor ligands |
| 01/31/2002 | CA2415362A1 Method for treating fibrotic diseases or other indications |
| 01/31/2002 | CA2415196A1 Cyclic substituted aminomethyl compounds and medicaments comprising these compounds |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415054A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | CA2415046A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2411192A1 Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation |
| 01/30/2002 | EP1176145A1 Novel guanidino derivatives as inhibitors of cell adhesion |
| 01/30/2002 | EP1175900A2 Use of growth hormone secretagogues for improvement of fucnctional health status |
| 01/30/2002 | EP1175490A2 Tyrosine kinase substrate (tks) proteins |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175445A1 Specific antibodies and antibody fragments for tgfbeta1 |
| 01/30/2002 | EP1175442A2 Osteopontin-derived chemotactic and inhibitory agents and uses therefor |
| 01/30/2002 | EP1175417A1 Substituted benzolactam compounds |
| 01/30/2002 | EP1175413A1 2,1-benzisothiazoline 2,2-dioxides |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175406A1 Imidazoline derivatives as alpha-1a adrenoceptor ligands |
| 01/30/2002 | EP1175404A1 Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| 01/30/2002 | EP1175400A1 Renin inhibitors |
| 01/30/2002 | EP1175398A1 Indoline derivatives as progesterone antagonists |
| 01/30/2002 | EP1175397A1 3,3-substituted indoline derivatives |
| 01/30/2002 | EP1175246A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| 01/30/2002 | EP1175223A2 Methods and compositions for modulating an immune response |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP1175213A2 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 01/30/2002 | EP0696919B1 Diagnosis and treatment of erectile dysfunction |
| 01/30/2002 | CN1333774A Substituted benzofuranodindoles and indenoindoles as novel potassium channel openers |
| 01/30/2002 | CN1333757A Quinazoline derivatives as medicaments |
| 01/30/2002 | CN1078462C Use of gossypol (and) its derivative as active component and use in preparation suppository in treating prostatitis |
| 01/29/2002 | US6342533 Antidepressants udes for bipolar and attention deficit disorders, hyperactivity, parkinson's disease, epilepsy, eating disorders |
| 01/29/2002 | US6342530 Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt |